Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.
作者信息
Muhiddin K A, Turner P
出版信息
Postgrad Med J. 1985 Aug;61(718):665-77. doi: 10.1136/pgmj.61.718.665.
Abstract
摘要
相似文献
1
Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.
Postgrad Med J. 1985 Aug;61(718):665-77. doi: 10.1136/pgmj.61.718.665.
2
The clinical pharmacology of antiarrhythmic drugs.
Cardiovasc Clin. 1984;14(3):153-90.
3
Antiarrhythmic agents.
Med J Aust. 1984 Nov 24;141(11):718-23.
4
New antiarrhythmic drugs: their place in therapy.
Drugs. 1981 Nov;22(5):363-400. doi: 10.2165/00003495-198122050-00002.
5
Potentially significant drug interactions of class III antiarrhythmic drugs.
Drug Saf. 2003;26(6):421-38. doi: 10.2165/00002018-200326060-00004.
6
A benefit-risk assessment of class III antiarrhythmic agents.
Drug Saf. 2002;25(12):847-65. doi: 10.2165/00002018-200225120-00003.
7
[Clinical evaluation of the anti-arrhythmic properties and cardiohemodynamic effects of the basic anti-arrhythmia agents].
Farmakol Toksikol. 1985 Jan-Feb;48(1):5-10.
8
[Classification and mechanism of action of anti-arrhythmia drugs].
Wien Med Wochenschr. 1994;144(14-15):338-42.
9
A rational scientific basis for subclassification of antiarrhythmic drugs.
Trans Am Clin Climatol Assoc. 1986;97:43-52.
10
Clinical pharmacology of antiarrhythmic drugs: a review and overview, part I.
Int J Clin Pharmacol Ther Toxicol. 1981 Apr;19(4):139-51.
引用本文的文献
1
Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach.
Front Cardiovasc Med. 2022 Apr 13;9:829484. doi: 10.3389/fcvm.2022.829484. eCollection 2022.
2
[Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].
Herzschrittmacherther Elektrophysiol. 2010 Dec;21(4):228-38. doi: 10.1007/s00399-010-0090-1.
本文引用的文献
1
The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.
Br J Clin Pharmacol. 1974 Feb;1(1):86-7. doi: 10.1111/j.1365-2125.1974.tb00214.x.
2
Antifibrillatory action.
J Physiol. 1962 Mar;160(3):470-82. doi: 10.1113/jphysiol.1962.sp006860.
3
Ventricular fibrillation precipitated by cardiac catheterization; complete recovery of the patient after 45 minutes.
J Am Med Assoc. 1950 Jun 24;143(8):717-20. doi: 10.1001/jama.1950.02910430009003.
4
APPLICATION OF DRUG METABOLISM TO DRUG TOXICITY STUDIES.
Ann N Y Acad Sci. 1965 Mar 12;123:273-86. doi: 10.1111/j.1749-6632.1965.tb12268.x.
5
QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.
Circulation. 1964 Jul;30:17-26. doi: 10.1161/01.cir.30.1.17.
6
INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.
Neurology. 1964 Jun;14:542-8. doi: 10.1212/wnl.14.6.542.
7
A comparison of tests for antifibrillatory action.
Br J Pharmacol Chemother. 1961 Dec;17(3):424-32. doi: 10.1111/j.1476-5381.1961.tb01129.x.
8
Urinary pH.
J Urol. 1959 Feb;81(2):339-43. doi: 10.1016/S0022-5347(17)66022-1.
9
Torsades de pointes as a manifestation of mexiletine toxicity.
Am Heart J. 1980 Dec;100(6 Pt 1):878-80. doi: 10.1016/0002-8703(80)90070-8.
10
Displacement of phenytoin from plasma binding sites by salicylate.
Clin Pharmacol Ther. 1980 Feb;27(2):165-9. doi: 10.1038/clpt.1980.25.
Zotero 插件